COVID-19 Vaccines Information for Clinicians...Dec 21, 2020 · COVID-19 Vaccines – How We Save Lives 4 Vaccines don’t save lives. Vaccinations save lives. COVID-19 Vaccines –

Maine DHHS

COVID-19 Vaccines Information for Clinicians

Stephen Sears, ME CDCLisa M. Letourneau MD, MPH, ME DHHS

December 21, 2020(Core Set)

Welcome

2

• Introductions• Session goals & format• CME available (0.5 AMA PRA Cat 1 Credit/session)If CME desired, pls enter your name & email in chat!(Note: if phone only, email your name & date of sessions attended to [email protected])

• Future sessions• Current context

mailto:[email protected]

The planners and faculty for this activity do not have any relevant financial relationships to

disclose with any Commercial Interests and do not have any conflicts of interest to resolve

3

Disclosures

COVID-19 Vaccines – How We Save Lives

4

Vaccines don’t save lives. Vaccinations save lives.

COVID-19 Vaccines – Info for Clinicians

5

• Context• Science of vaccines• Vaccine development & approval process• Initial vaccines• Vaccine distribution planning• Vaccine hesitancy & patient conversations• Vaccine storage, handling & administration• Reporting & tracking adverse events

6

Nucleic Acid Vaccines

US CDC: What Clinicians Need to Know About Pfizer-BioNTech COVID-19 Vaccine

https://www.cdc.gov/vaccines/covid-19/downloads/pfizer-biontech-vaccine-what-Clinicians-need-to-know.pdf

7

mRNA Vaccines: Pfizer & Moderna



8

Pfizer-BioNTech COVID-19 Vaccine



9

Pfizer Clinical Trial: Safety

US CDC: What Every Clinician Should Know COVID-19 Vaccine Safety

https://emergency.cdc.gov/coca/calls/2020/callinfo_121420.asp

Pfizer BioNTech• mRNA vaccine• Trial with >44,000• Efficacy 94.5%• Minimal adverse rxn’s• 2nd dose at 21D• Auth’d for ≥16yo• Storage at -70C• Can be refridg’d for 5D

Moderna• mRNA vaccine• Trial with >30,000• Efficacy >94.1%• Minimal adverse rxn’s• 2nd dose at 28D• Auth’d for ≥18yo• Storage at -20C• Can be refridg’d for 30D

10

Key Similarities & Differences

11

Ingredients of Pfizer & Moderna Vaccines

12

Pfizer Clinical Trial: Safety



13

Post-Vaccine Sx & Reactogenicity

14

US CDC: Prepare to Manage Anaphylaxis

US CDC: What Clinicians Need to Know Pfizer & Moderna Vaccines

https://emergency.cdc.gov/coca/ppt/2020/12.18.2020_COCA_Pfizer-BioNTech-and-Moderna_COMBINED-2.pdf

15

US CDC: Prepare to Manage Anaphylaxis

US CDC: What Clinicians Need to Know Pfizer & Moderna Vaccines

https://emergency.cdc.gov/coca/ppt/2020/12.18.2020_COCA_Pfizer-BioNTech-and-Moderna_COMBINED-2.pdf

Proposed Phases of COVID-19 Vaccination16-64 years with high -riskmedical conditions (>110M)

16-64 years Without high -risk

medical conditions(

17

Additional Consideration for Phase 1a • Limited initial supply means sub-prioritization needed• First supplies prioritized within Phase 1a to staff teams

in highest-risk units – i.e.– ICUs/ Critical Care Units– EDs– COVID units

• ME DHHS/CDC working to identify next 1a priority grps• Vaccinating clinical staff needs to anticipate /

accommodate likely vaccine reaction sx (may need to vaccinate in staff ‘waves’)

• Ongoing safety monitoring is critical

• Hospitals• Pharmacies

– Pharmacy Partnership for LTC (Walgreens, CVS)– Commercial pharmacies

• EMS• Enrolled/registered physician & dental

practices• Public health nursing

18

COVID-19 – Maine Vaccinators

Additional COVID Vaccine Resources

19

• HHS Fact Sheet Operation Warp Speed• NY Times Vaccine Tracker• ME COVID Vaccine Plan• ME CDC COVID-19 Vaccine Provider Portal• ME CDC COVID-19 Vaccine Info for Clinicians• ME CDC COVID-19 Vaccine Provider Enrollment• US CDC COVID-19 Vaccine Resources for Providers• US CDC COVID-19 Vaccine Training for Providers• US CDC Engaging Patients in COVID Vaccines• US CDC Answering Likely Questions on COVID Vaccine• FDA Issues EUA for Pfizer-BioNTech COVID-19 Vaccine

https://www.hhs.gov/coronavirus/explaining-operation-warp-speed/index.htmlhttps://www.maine.gov/dhhs/mecdc/infectious-disease/immunization/covid-19-providers/index.shtmlhttps://www.maine.gov/dhhs/mecdc/infectious-disease/immunization/covid-19-providers/index.shtmlhttps://www.maine.gov/dhhs/mecdc/infectious-disease/immunization/covid-19-providers/enrollment.shtmlhttps://www.cdc.gov/coronavirus/2019-ncov/hcp/vaccination.htmlhttps://www2.cdc.gov/vaccines/ed/covid19/SHVA/index.asphttps://www.cdc.gov/vaccines/covid-19/hcp/engaging-patients.htmlhttps://www.cdc.gov/vaccines/covid-19/hcp/answering-questions.htmlhttps://www.fda.gov/news-events/press-announcements/fda-takes-key-action-fight-against-covid-19-issuing-emergency-use-authorization-first-covid-19

20

ME CDC COVID-19 Vaccine Resources

ME CDC COVID Vaccine Resources

Vaccine questions? Email: [email protected]

https://www.maine.gov/dhhs/mecdc/infectious-disease/immunization/covid-19-providers/index.shtmlmailto:[email protected]

• Stephen Sears MD, MPHConsulting Epidemiologist, Maine [email protected]: 207-458-2351

• Lisa Letourneau MD, MPHSenior Advisor, Healthcare Delivery System Change, ME [email protected]: 207-415-4043

21Maine Department of Health and Human Services

Presenters

mailto:[email protected]:[email protected]

22

COVID-19 Vaccines

Questions??

Maine DHHSWelcomeDisclosuresCOVID-19 Vaccines – How We Save LivesCOVID-19 Vaccines – Info for CliniciansNucleic Acid VaccinesmRNA Vaccines: Pfizer & ModernaPfizer-BioNTech COVID-19 VaccinePfizer Clinical Trial: SafetyKey Similarities & Differences Pfizer Clinical Trial: SafetyPost-Vaccine Sx & Reactogenicity Slide Number 14Slide Number 15Proposed Phases of COVID-19 VaccinationAdditional Consideration for Phase 1a COVID-19 – Maine VaccinatorsSlide Number 19Slide Number 20Slide Number 21Slide Number 22

Documents

COVID-19 Vaccines Information for Clinicians...Dec 21, 2020 · COVID-19 Vaccines – How We Save Lives 4 Vaccines don’t save lives. Vaccinations save lives. COVID-19 Vaccines –